Extensively drug-resistant tuberculosis: current challenges and threats

FEMS Immunol Med Microbiol. 2008 Jul;53(2):145-50. doi: 10.1111/j.1574-695X.2008.00400.x. Epub 2008 May 8.

Abstract

Extensively drug-resistant tuberculosis (XDR-TB) is defined as tuberculosis caused by a Mycobacterium tuberculosis strain that is resistant to at least rifampicin and isoniazid among the first-line antitubercular drugs (multidrug-resistant tuberculosis; MDR-TB) in addition to resistance to any fluroquinolones and at least one of three injectable second-line drugs, namely amikacin, kanamycin and/or capreomycin. Recent studies have described XDR-TB strains from all continents. Worldwide prevalence of XDR-TB is estimated to be c. 6.6% in all the studied countries among multidrug-resistant M. tuberculosis strains. The emergence of XDR-TB strains is a reflection of poor tuberculosis management, and controlling its emergence constitutes an urgent global health reality and a challenge to tuberculosis control activities in all parts of the world, especially in developing countries and those lacking resources and as well as in countries with increasing prevalence of HIV/AIDS.

Publication types

  • Review

MeSH terms

  • Antitubercular Agents / pharmacology*
  • Communicable Disease Control
  • Drug Resistance, Multiple, Bacterial
  • Extensively Drug-Resistant Tuberculosis / epidemiology*
  • Extensively Drug-Resistant Tuberculosis / microbiology*
  • Humans
  • Mycobacterium tuberculosis / drug effects*
  • Prevalence

Substances

  • Antitubercular Agents